Redox cofactors are the molecular batteries of the cell. They accept and donate electrons in the tightly choreographed reactions that underpin respiration, photosynthesis, biosynthesis and detoxification. The canonical cofactors—molecules such as flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP)—are so widespread that their presence in an enzyme active site is often assumed rather than demonstrated. But over the past several years, researchers have identified a series of modified and entirely distinct cofactors: prenylated flavins such as flavin adenine dinucleotide modified with a prenyl group, deazaflavins like F420, quinone-derived cofactors such as topaquinone and tryptophan tryptophylquinone, and metal-organic species that defy easy classification. These noncanonical cofactors enable chemistries that standard flavins and nicotinamides cannot easily achieve, including hydride transfers at unusual redox potentials, radical-mediated rearrangements and C–C bond formations that would be difficult with conventional catalysis.

The central puzzle addressed in the new work is one of recognition and assembly. If an enzyme uses a noncanonical cofactor, how does the protein know to bind that cofactor rather than its more abundant canonical cousin? And how can bioinformaticians predict, from sequence alone, which of the millions of uncharacterized proteins in genomic databases depend on these exotic helpers? The answer, according to the study, lies in a short, recurring sequence motif—a conserved stretch of amino acids that acts as a molecular postcode, directing the enzyme’s cofactor-binding pocket toward noncanonical chemistry.

Sequence motifs have long served as the workhorses of computational biology. Short conserved patterns, such as the P-loop that binds nucleotide phosphates or the zinc-finger motifs that coordinate metal ions in DNA-binding proteins, allow researchers to assign function to proteins that have never been isolated in a laboratory. The newly identified motif performs a similar role for redox cofactor selection. By scanning families of flavin-dependent enzymes and comparing those known to use standard FAD or FMN with the smaller subset confirmed to use modified or alternative cofactors, the researchers identified a conserved pattern of residues that appears with striking regularity in the noncanonical group and is conspicuously absent from the canonical one. Mutational experiments confirmed that altering these residues in a noncanonical enzyme abolished its ability to accommodate the alternative cofactor, while introducing the motif into a canonical scaffold shifted its cofactor preference—a result that establishes the motif as a genuine determinant of cofactor identity rather than a coincidental correlation.

The implications of this finding extend well beyond the specific enzyme families examined in the study. Genomic surveys suggest that proteins carrying the motif are distributed across a remarkable range of organisms, from soil-dwelling actinobacteria—long recognized as prolific producers of bioactive natural products—to human-associated microbes and even some archaeal lineages. In many of these organisms, the motif-bearing enzymes cluster within biosynthetic gene clusters, the compact genomic neighborhoods that encode the assembly lines for antibiotics, antitumor agents and other specialized metabolites. This genomic context hints at a widespread and previously underappreciated role for noncanonical redox chemistry in natural product biosynthesis, suggesting that many of the structurally exotic metabolites isolated from microbes over the past half-century may owe their existence to enzymes quietly using cofactors that standard annotation pipelines would never flag.

One of the most exciting consequences of the work is predictive. Armed with the motif, researchers can now interrogate sequence databases with a simple pattern search and retrieve a curated list of candidate enzymes likely to use noncanonical cofactors. This transforms what has historically been a slow, serendipitous process—discover a strange metabolite, purify the enzyme responsible, and only then realize the cofactor is unusual—into a rational, hypothesis-driven workflow. Biochemistry can then be targeted at the most promising candidates, prioritizing enzymes from gene clusters associated with medicinally relevant compound classes. In an era when the rate of genome sequencing vastly outpaces the rate of experimental characterization, tools that convert sequence information into functional predictions are among the most valuable commodities in the life sciences.

The discovery also carries significant weight for synthetic biology and enzyme engineering. Noncanonical cofactors often possess redox potentials and reactivity profiles that canonical cofactors cannot match. F420, for example, the deazaflavin cofactor best known from methanogenic archaea, mediates hydride transfer reactions at potentials inaccessible to NAD and NADP, and engineered F420-dependent enzymes have already been explored for the degradation of persistent pollutants and the production of pharmaceutical intermediates. Prenylated flavins, meanwhile, catalyze photochemical reactions that ordinary flavins cannot, and their light-driven chemistry is being harnessed in optogenetic tools and photocatalytic cascades. A sequence-level handle on cofactor selection means that protein engineers can now rationally swap cofactor identity in designed enzymes, effectively reprogramming the electrochemical capabilities of a catalytic scaffold without altering its overall fold. This could accelerate the design of biocatalysts for green chemistry, where replacing metal catalysts and harsh reagents with enzyme-based alternatives is a major industrial goal.

From an evolutionary standpoint, the findings raise fascinating questions about how and why biology expanded its redox cofactor repertoire in the first place. The canonical cofactors are ancient, likely predating the last universal common ancestor, and their chemistry is deeply woven into core metabolism. Noncanonical cofactors, by contrast, appear to have arisen as evolutionary innovations in specific ecological and metabolic contexts—perhaps to exploit new redox niches, to escape the thermodynamic constraints of shared metabolic pools, or to protect specialized pathways from cross-talk with housekeeping chemistry. The presence of a dedicated sequence motif suggests that cofactor innovation was accompanied by co-evolution of the protein binding environment, producing a heritable, recognizable signature that could be propagated across enzyme families through duplication and divergence. In this sense, the motif is a fossil record of chemical innovation, preserving in amino acid sequence the memory of evolutionary experiments in electron transfer.

The study also serves as a cautionary tale for genome annotation. Most automated pipelines assign enzyme function by homology, and a protein that resembles a flavin-dependent monooxygenase is typically annotated as such, regardless of which cofactor it actually employs. If a substantial fraction of these enzymes in fact use noncanonical cofactors, then large swaths of existing functional annotations may be subtly or substantially wrong, with consequences for metabolic modeling, pathway reconstruction and the interpretation of gene-expression data. The motif provides a corrective lens, allowing annotators to flag proteins whose cofactor assignments deserve experimental scrutiny. As the authors and commentators in the field note, the lesson is broader: the most abundant cofactors are not necessarily the only ones, and assumptions baked into databases can obscure entire layers of biochemical diversity.

Looking forward, the identification of this sequence motif is likely to catalyze a wave of discovery across several fronts. Experimentalists will purify and characterize motif-bearing enzymes from diverse organisms, likely uncovering new cofactor structures and new reaction types. Computational biologists will refine the motif definition, searching for related patterns that govern the use of other exotic cofactors, and integrating these signals into machine-learning models of enzyme function. Structural biologists will determine how the motif residues reshape the cofactor-binding pocket at atomic resolution, providing design principles for engineered catalysts. And natural products chemists will revisit orphan biosynthetic gene clusters with fresh eyes, suspecting that many of the unexplained transformations encoded within them depend on redox chemistry that no one thought to look for. What began as a search for a short string of amino acids has ended with a map pointing toward a vast, unexplored territory of enzyme chemistry—one that has been hiding in plain sight within the genomes of organisms all around us, waiting only for the right pattern to reveal it.

Subject of Research: A conserved sequence motif that enables natural enzymes to use noncanonical redox cofactors

Article Title: A sequence motif enables widespread use of noncanonical redox cofactors in natural enzymes

Article References: Saleh, S., Hsu, N.-H., Luu, E., Martin, V. C., Ng, H. J. C., Black, W. B., Zhang, S., Kim, J.-K., Sankaran, B., Tran, A. H. T., Hayes, R. L., Siegel, J. B., Qiao, F., & Li, H. (2026). A sequence motif enables widespread use of noncanonical redox cofactors in natural enzymes. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02315-w

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02315-w

Keywords: redox cofactors, sequence motif, enzymes, flavin, natural product biosynthesis, genome annotation, enzyme engineering, deazaflavin F420, biocatalysis, protein evolution, biosynthetic gene clusters, Nature Chemical Biology

In the quest to unearth new natural products, scientists have remarried themselves to Actinomycetes using state-of-the-art genomics and metabolomics approaches. As genomes are sequenced and analyzed with increasing rapidity, researchers are beginning to unravel the complex biosynthetic pathways within Actinomycetes. This offers an unprecedented opportunity to identify and characterize novel compounds that may have significant applications in medicine and agriculture. It is their ability to produce secondary metabolites that makes Actinomycetes a treasure trove for drug discovery, particularly in an era where antibiotic resistance poses a harrowing threat to global health.

The drive toward discovering new natural products from Actinomycetes is further emboldened by the compelling success stories of already identified compounds. For instance, the discovery of Streptomycin from Streptomyces griseus marked a turning point in the treatment of tuberculosis, while Streptomyces aureofaciens yielded the powerful antibiotic Chloramphenicol. These groundbreaking findings serve as both motivation and compass for researchers delving into the metabolic capabilities of other Actinomycetes strains. The narrative established by these existing antibiotics establishes a legacy that current and future generations of scientists hope to build upon.

Researchers are using high-throughput screening techniques and advanced bioinformatics tools to probe the untapped reservoirs of actinobacterial biodiversity. Whole-genome sequencing provides a vista into the genetic diversity present in previously unstudied strains, often revealing cryptic biosynthetic gene clusters that have yet to be activated. Activation often requires tweaking environmental conditions or co-culturing with other microorganisms, presenting a new horizon for achieving previously inaccessible natural products. There is an emerging understanding that the ecological relationships within the microbial world can act as triggers for the expression of these complex biosynthetic pathways.

Moreover, scientists are harnessing synthetic biology to engineer Actinomycetes, allowing for the generation of novel compounds with desired pharmaceutical properties. Through techniques such as CRISPR-Cas9, researchers can edit and manipulate the genetic material of these organisms, optimizing their potential to produce new and innovative compounds. This intersection of synthetic biology and microbiology is redefining the landscape of natural product discovery, positioning Actinomycetes at the forefront of biotechnological advancements.

As research advances, it becomes increasingly evident that the natural product potential of Actinomycetes is not restricted to traditional antibiotics. Beyond the realm of antimicrobials, compounds with anti-cancer, anti-inflammatory, and neuroprotective properties are gaining attention. Current studies are beginning to elucidate the mechanisms through which these compounds operate, providing insights into their therapeutic applications. As a result, the push for Actinomycetes study is fueled not only by the urgent need for new antibiotics but also by a broader ambition to explore their multifaceted roles in promoting human health.

The environmental significance of Actinomycetes cannot be overlooked either. These microorganisms play essential roles in soil health and nutrient cycling, influencing plant growth and ecosystem dynamics. Understanding their functional potential could lead to advancements in sustainable agriculture, with compounds derived from Actinomycetes being used as natural pesticides or fertilizers. This facet underscores the importance of maintaining microbial diversity, as each species may possess unique traits vital for environmental balance and resilience.

In aligning scientific research with ecological sustainability, the exploration of Actinomycetes serves as a prime example of how our understanding of microbial ecosystems can coincide with global challenges. The potential for harnessing the natural world for medicine and bioproducts invites a renewed conversation about biodiversity conservation and responsible usage of microbial resources. Protecting microbial habitats ensures that we preserve the intricate web of life that has, and continues to, yield invaluable contributions to human society.

Looking ahead, the prospects for Actinomycetes in the realm of drug discovery remain promising. The integration of omics technologies with traditional microbiological techniques is culminating in a deeper understanding of how these organisms function and the potential they hold. As researchers continue to decode their complex genetic instructions, the enthusiasm for Actinomycetes is palpable. Every new finding serves as a reminder of the vast unknowns and potential that lurk within the microscopic world, waiting for enterprising scientists to uncover.

Ultimately, the story of Actinomycetes is just beginning. With continued advances in technology and a commitment to exploring these microorganisms, researchers are poised to revolutionize our understanding of natural products and their myriad applications. Undiscovered entities residing within Actinomycetes may hold the key to solving pressing health crises, offering innovative solutions that span the spectrum from human medicine to agricultural sustainability.

In conclusion, the undiscovered natural product potential of Actinomycetes stands as a beacon for both the scientific community and global society at large. These organisms not only exemplify the marvels of nature’s creativity but also embody the enduring quest for knowledge and understanding in the microbial world. As we delve deeper into their genetic blueprints, we inch closer to revealing the secrets of chemical compounds that may one day transform healthcare, agriculture, and the way we interact with our environment.

With each advancement, the narrative of Actinomycetes grows richer and more compelling, emphasizing their role not just as mere microorganisms but as pivotal agents of change and discovery in our relentless pursuit of harnessing the power of nature for the benefit of mankind.

Subject of Research: Natural product potential of Actinomycetes.

Article Title: The undiscovered natural product potential of Actinomycetes.

Article References:

Caraballo-Rodríguez, A.M., Cumsille, A., Magyari, S. et al. The undiscovered natural product potential of Actinomycetes.
J Antibiot (2025). https://doi.org/10.1038/s41429-025-00876-x

Image Credits: AI Generated

DOI: 02 December 2025

Keywords: Actinomycetes, natural products, drug discovery, microbiology, biotechnology, biodiversity.

Iridoids have fascinated scientists for decades due to their complex structures and potent bioactivities, ranging from anti-inflammatory to anticancer properties. Despite their significance, the biosynthetic route leading to these compounds, particularly in asterids, had remained incomplete, with one key enzymatic step elusive to researchers. The identification of iridoid cyclase now completes this biosynthetic map, providing clarity on how plants efficiently orchestrate the cyclization of precursor molecules to form the iridoid scaffold, a critical intermediate in producing a spectrum of iridoid-derived specialized metabolites.

The newly discovered iridoid cyclase exhibits a remarkable catalytic specificity, converting 8-oxogeranial into nepetalactol stereoisomers—products that serve as fundamental building blocks in the synthesis of various iridoids. This enzymatic transformation involves a precise cyclization mechanism, an intricate process where the enzyme guides molecular folding and bond formations that dictate the stereochemistry and overall architecture of the resulting iridoid compounds. Such mechanistic insights are invaluable, providing a molecular blueprint for synthetic biology endeavors aiming to harness these pathways for scalable production of iridoid-based therapeutics.

Integral to the study was the use of a multidisciplinary approach combining advanced genomic sequencing, protein structure analysis, and enzymatic assays. Researchers employed heterologous expression systems to isolate and characterize the enzyme’s activity, confirming its role through substrate feeding experiments and kinetic studies. This comprehensive methodology not only validated the enzyme’s function but also offered a window into its evolutionary origin, tracing how gene duplication events and selective pressures have honed iridoid biosynthesis in asterids over millions of years.

The discovery carries significant evolutionary implications, offering evidence for convergent evolution within specialized metabolite pathways. The iridoid cyclase’s structural framework shows unexpected similarities to unrelated enzyme families, suggesting that plants have independently evolved the ability to catalyze this cyclization reaction multiple times through distinct protein architectures. This convergence highlights the biochemical versatility of plant secondary metabolism and the dynamic evolutionary pressures shaping natural product diversity.

Beyond its academic impact, the identification of iridoid cyclase holds immense promise for practical applications. Iridoids and their derivatives are coveted in pharmaceutical research for their antimicrobial, anticancer, and neuroprotective properties. The ability to enzymatically produce iridoids with defined stereochemistry affords a powerful tool to generate these compounds more efficiently and sustainably, bypassing laborious extraction from native plants and chemical synthesis pathways that often suffer from low yields and environmental concerns.

Moreover, this discovery paves the way for metabolic engineering strategies in crop species, enabling the enhancement of plant defense mechanisms. Iridoids play crucial roles in deterring herbivores and pathogens; thus, modulating their biosynthetic pathways through targeted manipulation of iridoid cyclase expression may bolster plant resilience, contributing to sustainable agricultural practices and reduced reliance on chemical pesticides.

The detailed mechanistic elucidation of iridoid cyclase also offers insights relevant to synthetic biology platforms. By integrating this enzyme into microbial fermentation systems engineered to mimic plant secondary metabolism, production of complex iridoid compounds could be scaled up with high fidelity and consistency. This biotechnological innovation stands to revolutionize access to natural products traditionally sourced from slow-growing or geographically limited plant species.

Furthermore, the researchers’ structural characterization of iridoid cyclase via crystallography highlighted key amino acid residues responsible for substrate binding and catalysis. These findings suggest opportunities for protein engineering to enhance activity or alter product profiles, potentially leading to novel iridoid derivatives with improved pharmacological properties. Such protein engineering endeavors represent a frontier in natural product chemistry, blending structural biology with chemical innovation.

Importantly, this research underscores the continued importance of fundamental plant biochemistry in driving translational outcomes. The decade-long pursuit of the missing enzymatic step in the iridoid pathway exemplifies the synergy between curiosity-driven basic science and applied research goals. Comprehensive natural product pathway elucidation remains critical for developing next-generation therapeutics derived from botanical sources.

The broader ecological context of iridoid biosynthesis was also addressed, with the authors noting the ecological significance of iridoids in plant interactions. Iridoids act as chemical mediators influencing pollinator behavior, herbivore deterrence, and symbiotic relationships with microbes. By dissecting their biosynthesis, scientists gain clues into ecological dynamics and evolutionary pressures that have shaped plant metabolite repertoires.

As the field moves forward, this discovery will likely prompt reexamination of plant metabolic networks beyond asterids, encouraging searches for analogous enzymatic activities in other lineages. It may also influence the design of biosensors and analytical techniques aimed at detecting and quantifying iridoid-related metabolites in vivo, enhancing our capacity to monitor plant physiology and environmental responses.

Ultimately, the elucidation of iridoid cyclase as the linchpin enzyme driving cyclization in the iridoid pathway marks a pivotal moment in natural product research. It exemplifies how detailed enzymology and molecular biology can resolve longstanding biochemical puzzles, unlocking both theoretical understanding and practical techniques to exploit nature’s chemical repertoire. The ripple effects of this advance are poised to impact drug discovery, sustainable agriculture, and bio-based manufacturing for years to come.

The collective effort of Colinas, Tymen, Wood, and colleagues in this study not only addresses a fundamental biological query but also lays the foundation for innovative avenues to harness plant natural products. Their work stands as a testament to the power of integrated scientific approaches in unraveling the complexity of specialized metabolism, setting the stage for transformative progress in plant biochemistry and beyond.

Subject of Research: The biosynthesis of iridoids in asterid plants, specifically the enzymatic step catalyzed by iridoid cyclase.

Article Title: Discovery of iridoid cyclase completes the iridoid pathway in asterids.

Article References:
Colinas, M., Tymen, C., Wood, J.C. et al. Discovery of iridoid cyclase completes the iridoid pathway in asterids. Nature Plants (2025). https://doi.org/10.1038/s41477-025-02122-6

Image Credits: AI Generated